Thal, L.J., Kantarci, K., Reiman, E.M., Klunk, W.E., Weiner, M.W., Zetterberg, H., Galasko, D., Pratico, D., Griffin, S., Schenk, D. and Siemers, E. (2006) The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Disease and Associated Disorders, 20, 6-15. doi:10.1097/01.wad.0000191420.61260.a8

has been cited by the following article:

• TITLE: Comparison of protein concentrations in serum versus plasma from Alzheimer’s patients

  AUTHORS: Ryan M. Huebinger, Guanghua Xiao, Kirk C. Wilhelmsen, Ramon Diaz-Arrastia, Fan Zhang, Sid E. O'Bryant, Robert C. Barber

  KEYWORDS: Alzheimer’s Disease; Serum Proteins; Plasma Proteins

  JOURNAL NAME: Advances in Alzheimer's Disease, Vol.1 No.3, December 28, 2012

  ABSTRACT: Background: There is great interest in developing blood-based biomarkers for Alzheimer’s disease (AD); however, there is no consensus as to what blood fraction is most appropriate for analyzing particular markers. The current study provides empirical evidence regarding how blood-based proteins vary depending on whether they are assayed in serum or plasma. Methods: Weanalyzed concentrations of 100 proteins in matched samples of serum and plasma from 39 Caucasian AD participants from the Texas Alzheimer’s Research and Care Consortium bymultiplex immunoassay. Results: Concentrations of 40 proteins were highly correlated (r2≥ 0.75) between plasma and serum while the remaining proteins were moderately to weakly correlated (r2